Byotrol PLC Publication of accounts and temporary suspension (1616O)
30 Septiembre 2019 - 6:01AM
UK Regulatory
TIDMBYOT
RNS Number : 1616O
Byotrol PLC
30 September 2019
Byotrol plc
PUBLICATION OF AUDITED RESULTS
FOR THE YEAR ENDED 31 MARCH 2019
TEMPORARY SUSPENSION OF TRADING IN SHARES FROM 1 OCTOBER
Byotrol plc ("Byotrol" or "the Company") has today released its
Unaudited Preliminary Results for the year to 31 March 2019, which
show good progress over the year.
Whilst the Directors are confident in the Unaudited Preliminary
Results announcement and believe the statements are close to final
form, those statements still remain subject to change, and the
Group will not now be able to publish its audited annual report and
accounts for the year ended 31 March 2019 (the "Accounts") by 30
September 2019 as required by Rule 19 of the AIM Rules for
Companies .
The accounting and audit process has been extended this year by
the complexities with the accounting for the Medimark acquisition
and the restatement of our 2018 results for the effects of IFRS15.
We are now in the process of finalising the audit process for the
year and the Accounts will be published as soon as possible.
Dealings in the Company's ordinary shares will therefore be
temporarily suspended from 7.30 a.m. tomorrow, 1 October 2019,
until such time as the Accounts have been duly published in
compliance with AIM Rule 19.
As set out in the preliminary results issued earlier, the
Company continues to make good progress, had cash balances of
GBP2.8m at the year end and the Directors remain confident in the
outlook.
Enquiries:
Byotrol plc 01925 742 000
David Traynor - Chief Executive
Nic Hellyer - Chief Financial Officer
finnCap
Geoff Nash / Teddy Whiley - Corporate Finance 020 7220 0500
Richard Chambers - ECM
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer
of antimicrobial technologies, identifying, developing, formulating
and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies delivers powerful,
broad-spectrum efficacy, optimised against commonly-occurring and
industry-specific pathogens.
Founded in 2005, the Company seeks to develop and commercialise
advanced antimicrobial technologies that create easier, safer and
cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLMMMTMBIJBBL
(END) Dow Jones Newswires
September 30, 2019 07:01 ET (11:01 GMT)
Byotrol (LSE:BYOT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Byotrol (LSE:BYOT)
Gráfica de Acción Histórica
De May 2023 a May 2024